|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003483,
umls-concept:C0017262,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0069676,
umls-concept:C0185117,
umls-concept:C0360714,
umls-concept:C0392756,
umls-concept:C0666497,
umls-concept:C1135918,
umls-concept:C2911684
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2001-4-30
|
|
pubmed:abstractText |
1. It has been suggested that osteopontin promotes the development of atherosclerosis, especially under diabetic conditions. 2. In the present study, we found that NK-104, a new potent synthetic inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, reduced osteopontin expression both at protein and mRNA levels in cultured rat aortic smooth muscle cells. 3. The inhibitory effect of NK-104 was almost completely reversed by mevalonate, suggesting that mevalonate or its metabolites play important roles in the regulation of osteopontin expression. 4. Furthermore, oral administration of NK-104 (3 mg kg(-1) day(-1) for 7 days) effectively suppressed abnormally upregulated expression of osteopontin mRNA in the aorta and kidney of streptozotocin-induced diabetic rats. 5. These data support a notion that NK-104 is a suitable drug for the treatment of diabetic patients with hypercholesterolaemia.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-10329452,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-10413606,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-10712383,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-13252080,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-2175918,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-2682646,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-2698313,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-3431345,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-7566020,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-7799957,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-7826382,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-7909437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-7968073,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-8200973,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-8262332,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-8798445,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-8801446,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-9012655,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-9296275,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-9613910,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-9613915,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-9681568,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-9726243,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-9804809,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-9841303,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11325797-9987076
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0007-1188
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
133
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
83-8
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:11325797-Administration, Oral,
pubmed-meshheading:11325797-Animals,
pubmed-meshheading:11325797-Aorta,
pubmed-meshheading:11325797-Blotting, Western,
pubmed-meshheading:11325797-Cells, Cultured,
pubmed-meshheading:11325797-Diabetes Mellitus, Experimental,
pubmed-meshheading:11325797-Gene Expression Regulation,
pubmed-meshheading:11325797-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:11325797-Kidney,
pubmed-meshheading:11325797-Male,
pubmed-meshheading:11325797-Mevalonic Acid,
pubmed-meshheading:11325797-Muscle, Smooth, Vascular,
pubmed-meshheading:11325797-Osteopontin,
pubmed-meshheading:11325797-Quinolines,
pubmed-meshheading:11325797-RNA, Messenger,
pubmed-meshheading:11325797-Rats,
pubmed-meshheading:11325797-Rats, Wistar,
pubmed-meshheading:11325797-Sialoglycoproteins
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells.
|
|
pubmed:affiliation |
Second Department of Internal Medicine, School of Medicine, Chiba University, 1-8-1 Inohana, Chiba 260-0856, Japan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
